Characterizing the mechanism of action of lenalidomide in a mouse model by Hurst, Slater Nelson
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
Characterizing the mechanism of
action of lenalidomide in a mouse
model
https://hdl.handle.net/2144/14675
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
CHARACTERIZING THE MECHANISM OF ACTION OF LENALIDOMIDE IN 
A MOUSE MODEL  
 
 
 
 
 
by 
 
 
 
SLATER HURST 
 
B.A., Duke University, 2010 
 
 
 
 
 
      Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2014  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ©   2014 by 
       SLATER HURST 
       All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 Hee-Young Park, Ph.D.  
 Assistant Dean, Division of Graduate Medical Sciences 
 Professor of Biochemistry and Dermatology 
  
 
 
Second Reader   
 Benjamin Ebert, M.D., Ph.D. 
 Associate Professor of Medicine 
 Harvard University, School of Medicine 
 
 
 
  iv
DEDICATION 
 
 
 
 
I would like to dedicate this work to Dr. Benjamin Ebert and all members of the Ebert lab 
who assisted in the completion of this project.  
 
 
  
  v
ACKNOWLEDGMENTS 
 
I would like to acknowledge the help and guidance of Dr. Jan Kronke in the 
completion of this project. I would also like to recognize Dr. Hee-Young Park for her 
continued support.  
 
  
  
  vi
CHARACTERIZING THE MECHANISM OF ACTION OF LENALIDOMIDE IN 
A MOUSE MODEL  
 
SLATER HURST 
 
ABSTRACT 
 
Lenalidomide is an FDA approved immunomodulatory drug (IMID) that is highly 
efficacious in myelodysplastic syndrome with del(5q), multiple myeloma,  as well as 
other B cell malignancies.1 Furthermore, lenalidomide promotes a multitude of 
physiological effects, which include increased IL-2 cytokine production, inhibition of 
TNF alpha by monocytes and teratogenicity.3 The molecular mechanism of action 
responsible for these pleiotropic effects has eluded researchers for nearly 50 years.5 
Recently, we identified lenalidomide to bind to and activate CRBN E3 ligase to 
specifically ubiquitinate two lymphoid transcription factors named IKZF1 (Ikaros) and 
IKZF3 (Aiolos), resulting in their proteasomal degradation. Targeted depletion of IKZF1 
and IKZF3 inhibits growth of myeloma cells and IL-2 release in T cells, explaining two 
properties of the drug.8 Another identified lenalidomide regulated substrate of CRBN is 
casein kinase 1α (CSNK1A1), potentially connecting lenalidomide’s activity in MDS 
with del(5q).8 While lenalidomide promotes these effects in human cells, the drug does 
not show activity in murine cells.7 Using this distinction as a vehicle to study the 
lenalidomide-CRBN interaction, we tested human-mouse chimera CRBN proteins in 
  vii
order to characterize the region of CRBN that is critical for lenalidomide activity. We 
were able to identify a group of non-conserved amino acids on CRBN necessary for 
lenalidomide activity. A single amino acid substitution is responsible for the different 
effects observed in humans and mice. Our findings will not only allow for the use of 
murine models in the study of lenalidomide and its analogs, but also help provide further 
insight into the drug’s molecular mechanism.   
 
  
  viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………...iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ..................................................................................................................... vvi 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ........................................................................................... xii 
INTRODUCTION .............................................................................................................. 1 
Preface ........................................................................................................................ 1 
History of Thalidomide............................................................................................. 2 
Thalidomide Today ................................................................................................... 6 
Specific Aims/Objectives .......................................................................................... 9 
RESULTS ......................................................................................................................... 11 
METHODS ....................................................................................................................... 28 
DISCUSSION ................................................................................................................... 36 
  ix
REFERENCES ................................................................................................................. 38 
CURRICULUM VITAE ................................................................................................... 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  x
      LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Graphical presentation of thalidomide publications per 
year as reported by PubMed search. 
8 
2 Graphical presentation of lenalidomide publications per 
year as reported by PubMed search. 
9 
3 Proteomic analysis & ubiquitin profiling from SILAC in 
MM1S cells 
11 
4 Diagram that shows thalidomide modulation of CRBN 
ligase complex 
12 
5 Validation experiments of CRBN-CL4 substrates. 14 
6 MM1S cells treated for 24 hours with indicated 
concentration of drug. 
15 
7 mRNA levels from MM1S cells after lenalidomide 
treatment compared to DMSO 
17 
8 Ubiquitin and proteomic analysis from SILAC. 17 
9 HEL and KG-1 cells treated with indicated lenalidomide 
dosage. 
18 
10 Lenalidomide time course performed in KG-1 cells 19 
11 Affinity purification of mouse CRBN with thalidomide. 20 
12 Sequence alignment of hIKZF1, mIKZF1, hIKZF3, 
mIKZF3 along critical binding region. 
21 
13 Sequence alignment of mCSNK1A1 and hCSNK1A1. 21 
14 Amino acid sequence alignment of mCRBN and hCRBN. 22 
15 Over-expression of mCRBN and hCRBN in murine baf-3 
cell line with indicated lenalidomide treatment. 
23 
  xi
16 Over-expression of chimera CRBN proteins in baf-3 cells. 24 
17 Sequence alignment of mCRBN and hCRBN. 25 
18 Schematic presentation of CRBN chimera proteins. 25 
19 Over-expressing mutant hCRBN in baf-3 cells with single 
AA substitution. 
26 
20 Immunoblot showing over-expression of V9311 mutant in 
baf-3 cells 
27 
 
 
  
  xii
LIST OF ABBREVIATIONS 
 
CRBN-CL4……………………………………………………CRBN E3 Ubiquitin Ligase 
CRBN………………………………………………………………….............CRBN-CL4 
CSNK1A1…………………………………………………………Casein Kinase 1-Alpha  
hCRBN……………………………………………………………………...Human CRBN 
h/m CRBN…………………………………………………………………Chimera CRBN  
IKZF1……………………………………………………………………......Ikaros protein 
IKZF3……………………………………………………………………......Aiolos protein 
mCRBN……………………………………………………………………...Mouse CRBN 
m/h CRBN…………………………………………………………………Chimera CRBN  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  1 
INTRODUCTION 
 
 
Preface 
Over the past half century, the scientific community has witnessed dramatic 
changes in response to thalidomide’s role as a therapeutic agent. Originally discovered in 
an effort to synthesize antibiotics in post WWII Germany, the drug thalidomide would 
eventually forecast a dark and complicated shadow over the world. From the well-known 
side effects in pregnant women to the myriad of mechanisms that characterize the drugs 
efficacy, thalidomide represents a confounding element in the theater of cancer biology. 
Today, there are hundreds of clinical trials that incorporate thalidomide, or one of its 
several analogs, in hopes of improving already established therapies as well as 
identifying new areas of research.58 The company that currently sells thalidomide, 
Celgene corporation, is estimated to be worth upwards of 47 billion dollars, a financial 
testament to the drug’s remarkable impact on patient care around the world.53 Though 
FDA approved for use in multiple myeloma, as well as leprosy and other B cell 
lymphomas, the direct mechanism of action of lenalidomide in myeloma was not 
discovered until 2013, highlighting an unusual situation given to the drug’s prevalence 
and clinical efficacy.10  
While the last two decades have observed spectacular advances in our 
understanding of thalidomide, the drug’s early stages of development, and later 
emergence to market, are also worthy of note. The story of thalidomide holds great value 
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for the medical community. This one drug has shifted therapeutic landscapes, altered 
FDA approval paradigms and even puzzled researchers who represent the vanguard of 
academic medicine. As we understand more about thalidomide and its analogs, academic 
opportunities will continue to emerge and potentially lead the way for even greater 
therapeutic success through novel drug design. However, in order to truly appreciate the 
present day importance of thalidomide, the drug’s largely forgotten history must be 
brought to light.  
 
History of Thalidomide 
  Founded in 1946, Chemie Grünenthal GmbH was a family-operated 
pharmaceutical located in Stoldberg, Germany.59 Initial work by Grünenthal was aimed 
towards antibiotic production, a lucrative direction after the Second World War. By 1950, 
Chemie Grünenthal was not only selling penicillin, but also researching new, and more 
superior forms of antibiotics in hopes of capturing a larger market share.46   
While historical accounts differ, it became evident that Chemie Grünenthal 
wanted to push more drugs to market as fast as possible. As Brynner and Stephens 
illustrate in their book detailing the history of thalidomide, Chemie Grünenthal’s 
aggressive effort to manufacture simple antibiotics led to the rather accidental synthesis 
of a compound named alpha-phthalmidoglutamine.46 As with many other formulas before 
it, Chemie Grünenthal gave this novel compound a name and moved forward with basic 
research. The year is 1954 and “thalidomide” was just born.46 Chemie Grünenthal even 
obtained a twenty-year patent on the drug, testimony to the company’s interest in this 
  3 
rather unique compound.59  
Initial testing by Chemie Grünenthal, however, quickly uncovered that 
thalidomide could not be used as an antibiotic or an even a antihistamine.46 With the 
hopes of penetrating the profitable antibiotic market now destroyed, the company still 
remained committed to the drug’s future. As further testing proved fruitless, researchers 
eventually produced one exceptionally attractive result. Chief pharmacologist, Dr. 
Herbert Keller, discovered that thalidomide demonstrated an unusually favorable toxicity 
profile.46 As noted by Brynner and Stephens, Dr. Keller’s team tested thalidomide on 
numerous animals, all of which demonstrated a markedly high LD50.46 Short for lethal 
dosage, an LD50 value tell scientists how much drug or compound is needed to kill 
exactly one half of the tested cohort.  
This moment marks a dramatic turning point in the history of thalidomide. Dr. 
Keller and his team had demonstrated that the drug was virtually non-lethal in animals at 
high doses. However, since the drug lacked efficacy in alleviating disease, Chemie 
Grünenthal began searching for an application for this presumably non-toxic drug.  
“A drug in search of a disease” is a phrase often associated with thalidomide and 
it’s analogs. Today, it is not unusual for pharmaceutical companies to synthesize a 
compound and then subsequently determine what ailment, if any, that drug might find 
application in targeting. This was the case for thalidomide. Dr. Keller and his team were 
in search of anything that might find a connection to the drug.46 However, instead of 
pursuing a broad course of research, Chemie Grünenthal actually began to compare the 
structure of thalidomide to other known compounds. Fortuitously, thalidomide shared 
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similar structural elements to that of barbiturates, a class of drugs known for their 
sedative and tranquilizing effect on patients.55 In hindsight, thalidomide’s structure does 
not mirror that of sedatives, nor does structural similarity guarantee comparable clinical 
outcomes in patients. Yet, despite this moment of neglect for scientific truth, Chemie 
Grünenthal again moved forward with research, this time under the premise that 
thalidomide would find efficacy as a barbiturate.  
Having already tested thalidomide in animals, Dr. Keller’s team knew that this 
drug did not show sedation, or any similar effects.46 Despite the inconclusive scientific 
findings, the company decided to begin human trials. The company’s leadership, as 
Brynner and Stephens suggest, anticipated vast market potential for a non-lethal 
sedative.46 With the possibility of large profits clouding their vision, Chemie Grünenthal 
neglected to perform additional testing before providing humans with thalidomide. 
It should be noted that while 1950’s West Germany lacked federal oversight in 
regards to drug development and distribution, the worldwide scientific community had 
already established a list of chemicals and drugs deemed toxic to humans, in particular to 
fetal development.57 However, Chemie Grünenthal did not believe thalidomide was toxic, 
nor did they believe it would produce such devastating effects in children. The reason for 
this is because the scientists at Chemie Grünenthal are believed to have tested 
thalidomide in animals, including mice. Yet, drug treatment did not demonstrate limb 
malformations in animal models. This discrepancy between humans and mice will be 
discussed in detail at a later point in this paper.  
What took place next is still an issue of debate. Brynner and Stephens suggest that 
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Chemie Grünenthal simply began distributing thalidomide to doctors, friends and even 
company employees. Some historians link this rather unethical distribution of drugs as a 
lingering element of Nazi Germany, more specifically remnants of the Third Reich’s 
biological research programs.56 Whether or not the scientists working at Chemie 
Grünenthal had any legitimate connections to the Nazi regime, what we can say for 
certain is that thalidomide was rushed to market before adequate human testing.  
Beginning in 1957, thalidomide, now branded as Contergan, was available for 
over the counter sale in Germany.57 That very next year, the same drug was available in 
the UK under the name Distaval.57 Initial reactions to the drug were in fact quite positive. 
Thalidomide was in fact able to sedate patients, showed no toxicity and was not habit-
forming.57 Even more remarkable was the drug’s ability to stimulate sleep.59 While one 
of the main uses for the drug was in treating morning sickness in pregnant women, 
thalidomide found application in a number of clinical indications, such as respiratory 
disease, hypertension and even headaches.57 Thalidomide was like a wildfire, quickly 
moving from one place to the next. By 1960 thalidomide had reached Australia, Japan 
and even the United States.61  
Chemie Grünenthal had finally reached their goal. They brought to market a drug 
that was both profitable and efficacious, thus placing their company on a successful 
trajectory toward future earnings. However, by the early 1960’s, reports from physicians 
started to voice a connection between thalidomide use and serious side effects.57 Nerve 
damage to the hands and feet (polyneuropathy) surfaced in elderly patients across 
Germany.58 More troubling, however, were reports in 1961 that thalidomide was causing 
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unusual birth defects in children.61 Physicians reported limb malformations, among other 
deformities, present in children born to mothers who were taking thalidomide.   
Finally, on November 27th 1961, Chemie Grünenthal withdrew thalidomide 
from the market and informed everyone of the drug’s tragic side effects.59 Despite this 
withdrawal, thalidomide had already spent almost two years on the open market, 
consequently impacting thousands of families. While the exact number of cases varies by 
source, Chemie Grünenthal reports that nearly 10,000 people worldwide were effected by 
thalidomide.59  
As we look back on the history of thalidomide, it has become evident that limb 
malformations (phocomelia) were not the only phenotypes seen in patients. Other effects 
credited to thalidomide include ocular abnormalities, renal dysfunction, facial naevus, 
deformities of the outer ear and even heart disease.60/57 Even more telling than medical 
terminology are the sorrowing photographs of children born to mother’s who ingested 
this powerful drug.   
 
Thalidomide Today 
What transpired over the next several decades marks a large period of transition 
for thalidomide. Dramatic changes in drug oversight, legal proceedings against Chemie 
Grünenthal and greater scientific understanding of the drug all underline the public image 
of thalidomide in the 1970’s and 1980’s. While basic research into the molecular 
mechanisms of the drug continued, the usage of thalidomide was largely eliminated.  
However, in 1992, a small pharmaceutical company named Celgene acquired 
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the thalidomide patent and began in depth research into the drug’s properties and 
chemistry.62 Thalidomide had been known for years to help treat leprosy, owing to the 
drugs rather unknown immunomodulatory effects. As Celgene investigated the biology 
behind this claim, they eventually found that thalidomide’s capacity for use in treating 
human disease was far more compressive than originally thought.62 By 1996 Celgene had 
developed a second generation analog named lenalidomide and further suggested the 
drug’s indication in treating multiple myeloma, a cancer of the human plasma cell.62  
Between the mid 1990’s and today, thalidomide, lenalidomide and third 
generation analog polmalidomide have been reported to find application in many 
diseases. Though lenalidomide is FDA approved for use in only a handful of ailments, the 
drug’s presence in medicine, and research, has climbed to astonishing heights.20 As 
indicated by the two graphical representations below, the number of publications that 
involve a thalidomide analog has increased almost every year.  
  8 
 
Figure 1. Graphical presentation of thalidomide publications per year as reported by PubMed search. 
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Figure 2. Graphical presentation of lenalidomide publications per year as reported by PubMed search. 
 
 
Aims & Objectives 
As the clinical efficacy of these drugs expands, greater importance is placed on 
understanding the specific molecular mechanisms at play. The purpose of this paper is to 
not only expand our knowledge of lenalidomide in disease application, but also to 
provide usable data that will accelerate further research. In this paper we provide several 
lines of evidence to demonstrate a novel mechanism of action for lenalidomide in 
multiple myeloma. We also show that lenalidomide operates by modulation of an 
ubiquitin ligase complex, causing subsequent depletion of essential transcription factors 
in multiple myeloma cells.  
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findings regarding lenalidomide’s mechanism of action in multiple myeloma. Second, I 
introduce a possible explanation as to why lenalidomide shows no activity in murine cell 
lines. The specific aims of this thesis are outlined below.  
 
 
1.    Present evidence to show that lenalidomide modulates a CRBN E3 ligase 
complex. 
 2.   Demonstrate that lenalidomide causes the selective depletion of three 
substrates (IKZF1, IKZF3 & CSNK1A1). 
 3.     Demonstrate that through the cloning and testing of chimera (human-mouse) 
CRBN proteins we were able to identify non-conversed amino acids responsible for 
lenalidomide-CRBN interaction. 
 4.   Present evidence that one non-conserved amino acids determines whether 
lenalidomide is active and explains the different effects seen in humans and mice. 
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RESULTS 
 
 
Target Identification of Lenalidomide  
Our group used a lenalidomide derivative immoblizied to a bead in combination 
with a proteomic platform called SILAC (stable isotope labeling of amino acids in cell 
culture) to identify potential targets of lenalidomide.8 The results show that lenalidomide 
binds to the CRBN-DDB1-CUL4A-ROC1 E3 ubiquitin ligase (CRBN-CRL4) (figure 3C 
+ 3D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. From Kronke et al.8 Proteomic analysis & ubiquitin profiling from SILAC in 
MM1S cells. (A) Log2 ratios for individual K-e-GG sites of lenalidomide compared to DMSO 
treated cells (12 hours). 5µM MG132 were added for the last 3 hours. Each dot represents a unique 
K-e-GG site. (B) Log ratios of changes of protein abundance of lenalidomide versus DMSO 
treated cells (12 hours). Each dot represents a distinct protein group. (C+D) CRBN interaction 
analysis in cells treated for 6 hours with DMSO or 1 µM lenalidomide. Scatter plot shows log2 
changes of proteins pulled down by HA-CBRN and identified by MS in lenalidomide versus 
DMSO treated control cells. 
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Remarkably, our identification of the CRBN-CL4 interaction with lenalidomide 
was independently validated by Ito et al in 2010. Ito’s group found that thalidomide binds 
to the same CRBN E3 ligase complex. Their data illustrated that this thalidomide-CRBN 
interaction is directly responsible for the drug’s teratogenicity (figure 4).7 Even though 
Ito et al focused on CRBN modulating teratogenicity, the correlation between 
thalidomide and CRBN presents another line of evidence that our SILAC approach was 
successful in drug target identification. 
  
Figure 4: From Ito et al.7 Diagram that shows thalidomide modulation of CRBN ligase complex. Model 
demonstrates that normally CRBN acts to ubiquitinate substrates, which have important downstream 
targets, such as limb formation. However, when introduced with thalidomide, CRBN ubiquitin function is 
inhibited, thus altering downstream pathways. 
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Analysis of CRBN-CL4 Substrates 
 
Our hypothesis was that modulation of the CRBN-CL4 ligase complex via 
lenalidomide would induce changes to potentially important downstream proteins. We 
then sought to identify specific substrates that were regulated by this CRBN-CRL4 
ligase. Using SILAC-based quantitative mass spectrometry, we analyzed changes in both 
ubiquitination and overall protein levels after a 12-hour lenalidomide treatment. We 
performed these experiments in a multiple myeloma cell line named MM1S (figure 3).8 
We found that IKZF1 (Ikaros) and IZKF3 (Aiolos) were differentially ubiquitinated and 
subsequently depleted after treatment with lenalidomide. Furthermore, we also found that 
lenalidomide increases the binding of IKZF1 and IKZF3 to the CRBN ligase complex, 
suggesting that IKZF1 and IKZF3 are substrates of CRBN-CL4 (figure 3C + 3D). 
In order to confirm that IKZF1 and IKZF3 are direct substrates of CRBN-CL4, 
we validated our SILAC proteomic data and differential ubiquitination analysis with a 
series of in vivo and in vitro experiments. Broadly, the validation experiments aimed to 
demonstrate that lenalidomide would induce depletion of either endogenous or 
ectopically expressed IKZF1 and IKZF3. As discussed below, we then further 
characterized this putative mechanism as post-transcriptional.  
 Analysis by western blot shows that lenalidomide depletes both IKZF1 and 
IKZF3 in a dose-dependent manner (figure 5A). Primary multiple myeloma samples also 
demonstrate a comparable protein decrease after a 6 hour lenalidomide treatment (figure 
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5).8  
 
 
 
 
 
 
 
 
 
Figure 5. From Kronke et al.8 Validation experiments of CRBN-CL4 substrates. (A) Effects of 
lenalidomide on endogenous IKZF1 and IKZF3 in MM1S cells treated for 24 hours. (B) In vivo 
ubiquitination analysis of HA-tagged IKZF1 and IKZF3 expressed in MM1S cells treated for 1.5 hours 
with 100 nM Epoxomicin and the indicated concentrations of lenalidomide. The FK2 antibody detects 
covalently linked ubiquitin. (C) In vitro ubiquitination reaction of HA-IKZF3 coimmunoprecipitated with 
FLAG-CRBN from 293T cells and incubated in the presence or absence of E1 and E2 ubiquitin-
conjugating enzymes. Primary multiple myeloma samples were treated for 6 hours and analyzed by  
immunoblot. 
 
We hypothesized that the selective depletion of IKZF1 and IKZF3 was caused by 
increased ubiquitination. To validate this hypothesis we performed both in vivo and in 
vitro ubiquitination reactions. Our data demonstrates that lenalidomide induces 
ubiquitination of HA tagged IKZF1 and IKZF3 in vivo in MM1S cells (figure 5B). 
Analysis by immunoblot illustrates that lenalidomide doses between .1µM and 10µM 
produced increased poly-ubiquitination of IKZF1 and IKZF3, compared to our control 
DMSO treatment (represented by 0µM). To perform the in vitro ubiquitination reaction 
 of HA tagged IKZF3, we 
then incubated the reaction in the
enzyme (E1 & E2). Western blot assays show increased ubiquitination in 
lenalidomide, CRBN and E1/E2 enzymes 
We also demonstrated that thalidomide, along with
pomalidomide, both deplete IKZF1 and IKZF3 levels after 
cells (figure 6). All three drugs are IMIDs, but their increasing potency in vivo, as shown 
by immunoblot, is consistent with current literature.
Figure 6. From Kronke et al.
drug. Depletion of IKZF1 and IKZF3 are consistent with current literature regarding their potency. 
 
 
Post-transcriptional Mechanism
After establishing that IKZF1 and IKZF3 are direct substrat
ubiquitin ligase, we hypothesized that the selective depletion of these two
factors was a post-transcriptional event. 
 15
first co-immunoprecipitated FLAG-CRBN from 293T cells
 presence or absence of essential conjugating ubiquitin 
(figure 5C).  
 third-generation analog 
24-hour treatment in MM1S 
8
  
8
 MM1S cells treated for 24 hours with indicated concentration of 
 
es of the CRBN 
In order to show that only protein levels 
. We 
the presence of 
 
 
 transcription 
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decreased, and not mRNA levels, we treated MM1S cells with lenalidomide over a 48-
hour time course and then performed real-time quantitative PCR. Our results show that 
mRNA levels of Ikaros and Aiolos do not markedly change after lenalidomide treatment, 
thus providing evidence that lenalidomide activity is targeting protein levels and not 
transcripts (figure 7). This result is consistent with our hypothesis that modulation of the 
CRBN-CL4 ligase by lenalidomide causes proteasomal degradation.  
 
 
Figure 7. From Kronke et al.8 mRNA levels from MM1S cells after lenalidomide treatment compared to 
DMSO. Data shows that mRNA levels of IKZF1 and IKZF3 do not deplete after drug treatment. 
 
 
 
 
Identification of Casein Kinase 1α  
Our proteomic analysis identified, in addition to IKZF1 and IKZF3, nearly 150 
proteins that might bind to the CRBN-CL4 ligase complex. While these other targets did 
not score as high as Ikaros or Aiolos, they still represent other potential substrates or even 
co-factors for ubiquitin ligase activity. Interestingly, we found that casein kinase 1-alpha 
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(CSNK1A1) was ubiquitinated and subsequently depleted after treatment with 
lenalidomide (figure 8).  
 
Figure 8. Ubiquitin and proteomic analysis from SILAC. Shows CSNK1A1 as being differentially 
ubiquitinated, thus providing indication as a CRBN-CL4 regulated substrate.  
 
To confirm our SILAC findings that CSNK1A1 is a targeted substrate of the 
CRBN ligase complex, we performed multiple validation experiments. Firstly, we 
showed that CSNK1A1 protein levels decreased in a dose-dependent manner after drug 
treatment in multiple cells lines (figure 9). Importantly, showing that CSNK1A1 behaves 
in a similar fashion to IKZF1 and IKZF3 gave us another way to illustrate lenalidomide 
sensitivity through immunoblot. We then performed a lenalidomide time course to assess 
when the drug reaches peak activity in CSNK1A1 depletion (figure 10).  
 Figure 9.  HEL and KG-1 cells treated with indicated lenalidomide dosage. Immunoblot demonstrates 
CSNK1A1 depletion.  
 
Though not the focus of this paper, CSNK1A1 is an interesting target of 
lenalidomide due to its relation to myelodysplastic syndrome (MDS) with del(5q). 
Almost all patients with this particular form of MDS have haploinsufficient CSNK1A1 
gene expression levels.24
lenalidomide induced degradation of CSNK1A1. 
the Wnt/ b-Catenin signaling pathway, cell cycle regulation and DNA damage repair. 
Interestingly, MDS patients 
treatment.4 Currently, the direct therapeutic role of lenalidomide in MDS is still under 
debate. However, identification
light on the molecular mechanis
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 Therefore, cells with del(5q) may be more susceptible to 
Furthermore, CSNK1A1 is involved in 
with del(5q) are also highly sensitive to lenalidomide 
 of CSNK1A1 as a substrate of CRBN-
ms that underlie the drug’s efficacy.  
CL4 might shed 
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Figure 10. Lenalidomide time course performed in KG-1 cells. Shows depletion of CSNK1A1 occurring 
after roughly 5 hours treatment time.  
 
   
Current work is being conducted to establish both in vitro and in vivo 
ubiquitination immunoblots for CSNK1A1. Our hypothesis is that CSNK1A1 will show 
increased ubiquitination after lenalidomide treatment.  
 
Lenalidomide & Mice 
For years research involving thalidomide and lenalidomide has been hindered by 
the fact that mice and humans show different effects after drug treatment. Mice do not 
show teratogenicity when treated with thalidomide.29 Additionally, murine multiple 
myeloma models are insensitive to lenalidomide.29    
Our group decided to investigate the differential effects of lenalidomide seen in 
mice and humans. One of the biggest questions that we wanted to answer was simply: 
why does neither thalidomide nor lenalidomide not show activity in mice? The most 
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obvious answer is that lenalidomide does not bind to the murine version of CRBN-CL4 
E3 ligase complex. However, Ito et al demonstrates that thalidomide does in fact bind to 
the mouse CRBN (mCRBN), as shown below in their affinity purification experiments 
(figure 11).  
 
 
 
 
Figure 11. From Ito et al.7 Affinity purification of mouse CRBN with thalidomide. (B) Protein extracts that 
ectopically express FH-CRBN were collected from human and mouse tissues. These samples were then 
affinity purified using thalidomide beads.  
   
Our next hypothesis was that the substrates of CRBN are different in mouse cells 
compared to human cells. In other words, murine physiology might not incorporate 
substrates such as Ikaros, Aiolos or even Casein Kinase 1 alpha, thus conferring 
lenalidomide insensitivity. However, IKZF1 and IKZF3 show homology when the amino 
acid sequences are compared and are highly homologous in the identified 58 amino acid 
degron sequence (figure 12).8 More specifically, murine and human versions of IKZF1 
and IKZF3 show 100% homology in the critical region.8 Casein kinase also shares 
dramatic similarity when comparing the murine and human versions of the protein.  
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Figure 12. Sequence alignment of hIKZF1, mIKZF1, hIKZF3, mIKZF3 along critical binding region.  
 
 
 
Figure 13. Sequence alignment of mCSNK1A1 and hCSNK1A1. Amino acid sequence indicates 
homology between species. 
 
Since the regulated substrates of CRBN-CL4 appear comparable, we concluded 
that this is probably not the reason why mouse cells are insensitive to lenalidomide. We 
then asked if there is a functional difference in the CRBN complex itself. If murine 
CRBN is functionally, or structurally, distinct from human CRBN (hCRBN), then this 
could account for the well-documented murine insensitivity.7 If you compare the amino 
 acid sequences of hCRBN
homologous (figure 14).  
Figure 14. Amino acid sequence alignment of mCRBN and hCRBN. 
 
Our initial experiment was designed to validate our immunoblot readout by 
demonstrating murine insensitivity to lenalidomide. 
cell line (murine cell line) and 
Since previous experiments 
treatment, we decided to use this depletion
Furthermore, previous experiments 
insensitive to lenalidomide. 
with lenalidomide to again show murine insensitivity to the drug. 
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 and mCRBN, we see that the proteins are not completely 
 
For this experiment we used a baf
retro-virally over-expressed either mCRBN or hCRBN. 
showed that CSNK1A1 levels decrease after lenalidomide 
 as an easy readout to test drug susceptibility
(not shown here) demonstrate that baf
In this experiment we also treated un-transduced baf
 
 
-3 
. 
-3 cells are 
-3 cells 
 As shown in figure 15, w
response to lenalidomide treatment in baf
mCRBN (figure 15). While the mCRBN shows a small level of sensitivity to the drug, it 
is clear that hCRBN activity is heavily modulated by lenalidomide ov
complex. Regular baf-3 cells that were not transfected with ectopically expressed CRBN 
show resistance to lenalidomide treatment. 
suggesting that the lack of lenalidomide 
complex itself.  
   
 
Figure 15. Over-expression of mCRBN and hCRBN in murine baf
treatment. mCRBN demonstrates insensitivity to lenalidomide, where as over
susceptibility.   
 
 
In order to further examine our findings, we cloned chimera CRBN proteins that 
consisted of either human or mouse amino acid sequences. 
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e see a dose-dependent depletion of casein kinase in 
-3 cells over-expressing hCRBN compared to 
er the murine liga
This data proved our hypothesis correct, 
activity in mice is due to the CRBN E3 ligase 
 
-3 cell line with indicated lenalidomide 
-expressing hCRBN confers 
The chimera prot
se 
eins were 
 designed to fuse half of the amino acid sequence from one species with half of the amino 
acid sequence from the other specie. 
express either m/hCRBN or h/mCRBN. 
protein as murine and C-terminus
mouse/human chimera shows greater sensitivity to lenalidomide than
chimera when over-expressed in baf
critical site for lenalidomide activity is
sequence of CRBN.  
 
Figure 16. Over-expression of chimera CRBN 
in response to lenalidomide when the 
plasmids. 
 
Next, we looked back at the amino acid sequence
specifically, we found that there are only 5
protein where the two species do not 
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We then retrovirally infected baf-3 cells to over
m/hCRBN indicates the N-terminus
 as human (figure 18). As our data illustrates, the 
 the 
-3 cells (figure 16). This result suggests 
 located in the second half of the amino acid 
plasmids in baf-3 cells.  Result shows CSNK1A1 depletion 
m/hCRBN is over-expressed, comparatively to other expressed 
s of mCRBN and
 amino acids in the second half of the CRBN 
exhibit exact homology (figure 17). 
-
 of the 
human/mouse 
that the 
 
 hCRBN. More 
 
 Figure 17. Sequence alignment of mCRBN and hCRBN. Amino acid 
outlined in black.  
 
 
 
  
 
 
Figure 18. Schematic presentation of CRBN chimera
 
 
We then hypothesized that if we substitute these single amino acids that are not 
homologous between human and mouse, we might be able to identify which amino acids 
are essential for lenalidomide sensitivity. 
substituted each of the non
 25
non-homologous matches are 
 
 proteins.  
We first used our m/hCRBN chimera and 
-homologous amino acids. As our immunoblot indicates, over
 
-
 expressing mutant V387I confers insensitivity to lenalidomide. 
single, non-conserved amino acid is responsible for lenalidomide’s activity.
 
 
Figure 19. Over-expressing mutant hCRBN in baf
murine cell line. Shows that we can confer insensitivity to human CRBN when we 
that mimics the murine AA at that site
 
 
  
 
Based on the previous
substituted the same amino acid so that it resembled hCRBN, this would confer 
sensitivity to lenalidomide (figure 20). 
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This result suggests that a 
 
-3 cells with single AA substitution. P
substitute
.  
 result, we then hypothesized that if we took 
 
 
erformed in 
 a single AA 
h/mCRBN and 
  
 
Figure 20. Immunoblot showing over
both hCRBN compared and mutant plasmids. 
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-expression of V9311 mutant in baf-3 cells.  CSNK1A1 depletion in 
Shows h/mCRBN with single amino acid substitution.
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METHODS 
 
 Many of the procedures outlined below are adapted from Kronke et al, citation 
number 8 in the references section. I, Slater Hurst, am a listed author of the publication. 
Furthermore, many of the protocols are specific and cannot be re-written.  
 
 
Viability 
 
For assessing the effects of lenalidomide on cell growth cells were plated in a 96-
well plate and treated with lenalidomide. On the respective days, total cellular ATP 
content was assessed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega) 
according to the protocol. Luminescence was assessed by a multimode detector DTX880 
(Beckman Coulter). 
 
In vitro ubiquitination 
 
293T cells were co-transfected with HA-IKZF3 and FLAG-CRBN. After 48 
hours cells were treated with DMSO or 1µM lenalidomide for exactly 20 minutes, lysed 
in IP lysis buffer (Pierce) and immunoprecipitation was performed overnight with anti-
FLAG M2 sepharose beads (Sigma) to obtain CRBN together with CRBN-bound IKZF3. 
The beads were then washed 3x with IP lysis buffer (Pierce), 1x ubiquitination buffer 
(Boston Biochem) and eluted with 250 µg/ml FLAG peptide (Sigma) for 30 min at 4°C. 
The CRBN-IKZF3 complex was incubated for 90 min at 30°C in the ubiquitination 
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reaction mixture. This mixture contained 900 ng E1, 1200 ng UbcH5a, 1200 ng UbcH5b, 
20 µg ubiquitin, 1 µM ubiquitin aldehyde, 1xubiquitin reaction buffer, 1xEnergy 
Restoration System (all Boston Biochem), and 100 nM MG101 in a total volume of 75 
µl. Negative controls did not include E1 and E2 enzymes. 20 µl of the reaction was 
denatured by adding 5x SDS containing loading buffer (Boston Biochem) and boiling at 
95°C for 5 minutes, separated by SDS-PAGE and transferred to a PVDF membrane in 
order to detect HA-IKZF3 and its ubiquitinated forms with an HA specific antibody. The 
remaining 55 µl reaction mix was denatured by adding SDS to a final concentration of 
1% and boiling for 10 minutes. 500 µl IP lysis buffer was added for 30 minutes before 
adding anti-HA magnetic beads (Miltenyi) for 1 hour. After purification on Multimacs 
columns (Miltenyi) eluates were separated by SDS-PAGE, transferred to a PVDF 
membrane and stained with an antibody detecting ubiquitin conjugates (FK2). 
 
In vivo ubiquitination 
 
MM1S and 293T cells ever-expressing tagged IKZF1 or IKZF3 were treated with 
the indicated concentrations of lenalidomide and/or 100 nM epoxomicin (EMD 
Biosciences) for 1.5 hours. Cells were then washed 2X with cold PBS and lysed under 
denaturing conditions using 2% SDS containing lysis buffer and boiled for 10 minutes at 
95°C. The SDS was diluted with the addition of 10x IP lysis buffer (Pierce) and 
incubated at 4°C for 30 minutes. Immunoprecipitation and western blot analysis was 
performed as described above. For assessment of endogenous ubiquitination of IKZF1 
and IKZF3 40x106 MM1S cells were treated with DMSO or lenalidomide for 1 hour and 
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then lysed in IP lysis buffer containing 10 mM NEM and 10µM MG132. Ubiquitinated 
proteins were pulled down by Ubiquilin 1 Tandem UBA (TUBE2) Agarose (Boston 
Biochem) for 4 hours at 4°C and washed 3x with IP lysis buffer. Lysates were separated 
by SDS-PAGE, transferred to PVDF membrane and probed with anti-IKZF3, anti-IKZF1 
and FK2. 
 
Immunoprecipitation 
 
For immunoprecipitation of HA-tagged proteins, the HA-protein Isolation Kit 
from Miltenyi was used according to the manufacturer’s protocol using a MultiMACS 
M96 Separator (Miltenyi). Proteins tagged with the FLAG peptide were 
immunoprecipitated using anti-FLAG M2 Affinity Gel (Sigma-Aldrich) according to the 
manufacturer’s protocol. Endogenous CRBN was immunoprecipitated using 
mouse polyclonal anti-CRBN (Abcam) and protein A magnetic beads (Miltenyi). Protein 
lysates were incubated together with the specific bead-bound antibody for 4 hours or 
overnight. Lysates were washed 2 to 4 times with RIPA or IP lysis buffer (Pierce) and 
protein was eluted from the affinity gel. 
 
 
 
Western blot and antibodies 
 
Protein lysates were run on Tris-HCl, 1mm Criterion™ Precast gels (Bio-Rad) at 
a constant voltage (200V). Proteins were transferred onto Imobilon-P transfer membranes 
(Millipore) at constant amperage (.6A). Before staining with primary antibodies, blots 
were blocked in 5% non-fat dry milk (SantaCruz) or BSA in TBST for 30 minutes. 
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For protein detection primary antibodies detecting HA (HRP-conjugate, Miltenyi, GG8-
1F3.3), FLAG (M2, HRP-conjugate Sigma Aldrich), Actin (HRP-conjugate, Abcam), 
rabbit IKZF3 (Imgenex), rabbit IKZF1 (H-100, Santa Cruz), FK2 (HRP-conjugate, Enzo 
Lifescience), rabbit CRBN (Proteintech), mouse CRBN (Abcam), goat CSNK1A1 
(Abcam), rabbit DDB1 (Abcam), rabbit CUL4A (Abcam), rabbit IRF4 (Cell Signaling) 
and rabbit p27 (Cell Signaling) were used. 
 
Quantitative RT-PCR 
 
Gene expression was measured by reverse transcription quantitative PCR (RQ-
PCR). For RNA isolation and reverse transcription the cDNA synthesis Kit for 
Multimacs (Miltenyi) was used according to the manufacturer’s protocol. The following 
primer-probe sets from Life Technologies were used: GAPDH (402869), IKZF1 
(Hs00958474_m1), IKZF3 (Hs00232635_m1), CRBN (Hs00372271_m1), 
IL-2 (Hs00174114_m1), IRF4 (Hs01056533_m1). Analysis was performed on a 7900HT 
Fast Real-Time PCR System (Applied Biosystems) in a 384-well plate. Relative 
expression levels were calculated using the ∆∆CT method. 
 
Transfections, Virus Production and Infections 
 
Retro- or lentiviral vectors were transfected together with plasmid encoding 
packaging proteins and VSV-G using TRANS-LTI (Mirrus) into 293T cells. The media 
was changed after 24 hours, and the viral supernatant was collected 36 hours and 48 
hours after transfection. For viral infection, cells were seeded in high density and 
supplemented with 1 to 2 µg/ml Polybrene (Sigma). Primary T cells were stimulated with 
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100 U/ml IL-2 on plates pre-coated with anti-C3/CD28 10 for 48h before lentiviral 
transduction. Puromycin selection was started 1 day after transduction at concentrations 
between 0.5 and 2 µg/ml. 
 
Plasmids and Virus constructs 
 
cDNAs were over-expression in the RSF91 retrovirus backbone (kind gift of 
Christopher Baum, Hanover Medical School). For certain experiments GFP was replaced 
by Tomato for competition experiments or GFP-T2A-Puro to allow for selection of 
positively transduced cells. The Gateway Vector Conversion System (Invitrogen) was 
used to convert RSF91 to a Gateway Destination vector. Entry clones were obtained from 
the Broad Institute Orfeome collection and cloned into RSF91-Gateway with LR clonase 
enzyme mix II (Invitrogen). IKZF4 cDNA was obtained from GeneCopeia. Mutations in 
CRBN, IKZF3 and IKZF4 were cloned by PCR using overlapping primers containing the 
respective mutations or deletions. The dominant negative IKZF3 mutant corresponds to 
isoform 12 that lacks 9 amino acids 55 to 275 comprising all 4 N-terminal Zinc Finger 
domains that are necessary for binding DNA. IKZF3 Isoform 12 is a dominant negative 
mutant for IKZF3 and IKZF1 by its ability to form homo- and heterodimers with IKZF1. 
 
K-ε-GG and proteome MS data analysis 
 
MS data was analyzed with the MaxQuant software version 1.3.0.5 and searched 
against the human Uniprot database that contained 248 common laboratory contaminants 
was provided by the MaxQuant software package. The search parameters were as 
follows: enzyme specificity was set to trypsin, maximum number of mixed cleavages set 
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to 2, precursor mass tolerance was at 20 ppm for the first search, and set to 6 ppm for the 
main search. Oxidized methionines and N-terminal protein acetylation were searched as 
variable modifications, with carbamidomethylation of cysteines searched as a fixed 
modification. For searching K-ε-GG data files, Gly-Gly addition to lysines was also 
searched as a variable modification. The minimum peptide length was set to 6, and false 
discovery rate for peptide, protein, and site identification was set to 1%. The filter labeled 
amino acids and peptide quantification functions were enabled. For proteome data, 
proteins were considered in the dataset if they were identified by 2 or more razor/unique 
peptides and quantified by 3 or more ratio counts in both biological 
replicates. For the K-ε-GG data, K-ε-GG sites were considered if they were confidently 
localized (>0.75) and quantified in all three biological replicates. 
 
 
 
Reagents  
 
Lenalidomide (Toronto Research Chemicals), Thalidomide (Milipore), 
Pomalidomide (Selleckchem) and MLN4924 (Active Biochem) were dissolved in DMSO 
at 10 to 100 mM and stored at -20°C for up to 6 months.  
 
Cell lines and primary cells  
 
MM1S, NCI-H929, U266, Namalwa, Jurkat, K562, HEL and 293T cells were 
obtained from American Type Culture Collection (ATCC). KMS-12BM was obtained 
from German Collection of Microorganisms and Cell Cultures (DMSZ). KMS-27, KE-97 
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and OPM-2 cells were provided by the cancer cell line encyclopedia (CCLE). Cells were 
cultured in RPMI 1640 (Mediatech) or DMEM (Mediatech) supplemented with 10-20% 
heat-inactivated fetal bovine serum (FBS)(Omega Scientific) and 1% penicillin, 
streptomycin, and humidified incubator under 5% CO2.  
Primary cells from patients with multiple myeloma and T cells from healthy donors 
were collected under an Institutional Review Board approved protocol at the Dana-Farber 
Cancer Institute.  PBMCs were isolated using Ficoll (GE Healthcare) according to the 
protocol. T cells were positive selection with CD3+ MACS beads (Miltenyi) and cultured 
in RPMI with 10% human Serum (Sigma) and 100 U/ml recombinant IL-2 (Miltenyi). T 
cells were activated on tissue culture plates pre-coated with 2.5 µg/ml CD3 (OKT3, 
Biolegend) and CD28 (CD28.2, Pharmingen). For re-stimulation and co-treatment with 
lenalidomide after lentiviral infection Dynabeads Human T Activator CD3/CD28 were 
added to the media.  
Primary myeloma cells were selected with CD138+ MACS beads (Miltenyi) and 
cultured in RPMI with 10% FBS.  
Synthesis of lenalidomide derivative  
 
NMR spectra were recorded on Bruker DRX-600, DRX-500, and AMX-400 
instruments and calibrated using residual undeuterated solvent as an internal reference 
(CHCl3 @ 7.26 ppm 1H NMR,  
77.16 ppm 13C NMR). The following abbreviations (orcombinations thereof) were used 
to explain the multiplicities: s = singlet, d = doublet, t = triplet, ap = apparent, m = 
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multiplet, b = broad, ABq = AB quartet.  
Compounds were purified by mass-directed purification on a Waters 
Autopurification system (Milford, MA). Collection was triggered on the (M+H)+ and 
(M+Na)+ ions on a ZQ mass spectrometer using positive electrospray ionization. Mobile 
phase A consisted of 0.2% ammonium hydroxide in water, while mobile phase B 
consisted of 0.2% ammonium hydroxide in acetonitrile. An initial hold at 0% mobile 
phase B for 1.0 minute was followed by a gradient from 0% to 100% mobile phase B 
over 11.0 minutes at 24 mL/min. A 2.0 mL/min at-column dilution was present using 
100% acetonitrile as well as a 2.0 mL/min make-up flow using 90/10/0.1 
methanol/water/formic acid. An XBridge OBD Prep C18, 5 µm, 19x100 mm column was 
used at room temperature.  
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DISCUSSION 
 
The mechanism of action of lenalidomide has eluded researchers for nearly 50 
years. Moreover, the pleiotropic effects modulated by this single drug have made the 
investigation of lenalidomide difficult. In 2013, we proposed a mechanism of action 
responsible for lenalidomide’s efficacy in multiple myeloma. This research demonstrated 
that lenalidomide binds to and modulates a CRBN-CL4 E3 ligase complex. We also 
found that lenalidomide causes selective depletion of two important transcription factors 
of the zinc-finger protein family, named IKZF1 and IKZF3. We then identified another 
substrate, CSNK1A1, which exhibits depletion in a similar fashion to Ikaros and Aiolos.  
 We continued to investigate the interaction of lenalidomide and CRBN by 
studying the drug’s insensitivity in murine cell lines. We concluded that lenalidomide’s 
lack of activity in murine cells is derived from its inability to properly activate the murine 
CRBN ligase complex, essential for downstream pathophysiology. We identified a 
specific region of CRBN that is responsible for lenalidomide sensitivity by cloning 
human-mouse chimeric CRBN proteins. Finally, we demonstrated that a single amino 
acid substitution in CRBN will confer insensitivity to the drug. 
 The identification of a primary target of lenalidomide has made possible the 
expansion of therapeutic approaches given the drug’s unique mechanism of action.   
Activation of the CRBN E3 ligase by lenalidomide provides a previously undescribed 
mechanism of a drug. Ikaros and Aiolos are important proteins in multiple myeloma, and 
their resultant depletion after lenalidomide treatment provides evidence that this putative 
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mechanism correctly characterizes the drug’s efficacy in patient treatment. Typically, 
proteins such as IKZF1 and IKZF3 are considered to be “undrugable.”  However, our 
data shows specificity in their depletion by ubiquitin ligase modulation. This finding 
might accelerate the synthesis of novel drugs that target proteasomal degradation 
mechanisms. Moreover, knowing the specific mechanism of action might enable 
researchers to synthesize lenalidomide analogs that are both safer and more efficacious 
for patients. 
Ultimately, however, lenalidomide is not a curative treatment for multiple 
myeloma. The majority of patients will eventually relapse or even becomes resistant to 
lenalidomide.20 Further research is still needed in order to establish the pathophysiology 
behind resistance mechanisms.  
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